Danny Sheng Wu Yeung Purchases 17,181 Shares of Prenetics Global (NASDAQ:PRE) Stock

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung acquired 17,181 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average cost of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the acquisition, the chief executive officer owned 112,416 shares in the company, valued at $2,386,591.68. This represents a 18.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Thursday, August 20th, Danny Sheng Wu Yeung bought 7,500 shares of Prenetics Global stock. The stock was purchased at an average price of $18.31 per share, with a total value of $137,325.00.

Prenetics Global Price Performance

Shares of PRE opened at $23.25 on Wednesday. The firm has a market cap of $392.23 million, a P/E ratio of -5.59 and a beta of 0.26. The stock has a 50 day simple moving average of $19.12 and a two-hundred day simple moving average of $18.93. Prenetics Global Limited has a 1 year low of $7.25 and a 1 year high of $23.63.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.31. The firm had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. On average, equities analysts anticipate that Prenetics Global Limited will post -1.86 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on PRE shares. Benchmark boosted their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Finally, Wall Street Zen raised Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prenetics Global presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Prenetics Global during the 4th quarter valued at approximately $1,302,000. 683 Capital Management LLC bought a new position in shares of Prenetics Global during the fourth quarter valued at approximately $1,181,000. Millennium Management LLC bought a new position in shares of Prenetics Global during the fourth quarter valued at approximately $810,000. Marshall Wace LLP purchased a new stake in Prenetics Global in the fourth quarter worth $788,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Prenetics Global in the fourth quarter worth $665,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.